Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)

Chengcheng Fu, Xuhong Fu, Bing Chen, Qingsong Yin, Songfu Jiang, Jingjing Shang, Chaoyang Guan, Song Jin, Yingying Zhai, Xiuyi Song, Xiaobao Yang, Depei Wu

Blood (2025) 146 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2025-2278

Published: 2025

Journal Articles

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Huanxin Zhang, Yi Wang, Chengcheng Fu, Yanli Feng, Yang Liu, Jing Wang, Chunrui Li, Wenming Chen, Zhenyu Li

Blood (2025) 146 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2025-2270

Published: 2025

Journal Articles

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Xiaozhe Li, Chengcheng Fu, Chunrui Li, Song Jin, Di Wang, Huixing Zhou, Jingjing Shang, Guangzhong Yang, Wenming Chen, Juan Li

Blood (2025) 146 (Supplement 1): 7588.

https://doi.org/10.1182/blood-2025-7588

Published: 2025

Journal Articles

Sustained MRD negativity via multimodal NGS/NGF overcomes high-risk cytogenetics and predicts long-term survival in transplant-eligible multiple myeloma: A real-world cohort study

Yuhe Peng, li Yao, Mingqing Zhu, Hongying You, Yan Xie, Zhi Yan, Weiqin Yao, Shuang Yan, Yingying Zhai, Jingjing Shang, Song Jin, Lingzhi Yan, Depei Wu, Chengcheng Fu

Blood (2025) 146 (Supplement 1): 5796.

https://doi.org/10.1182/blood-2025-5796

Published: 2025

Journal Articles

Treatment of high-risk newly diagnosed multiple myeloma with minimal residual disease-guided therapy：daratumumab, carfilzomib, lenalidomide, and dexamethasone (DKRd)

Hongying You, Zhi Yan, Yingying Zhai, Weiqin Yao, Shuang Yan, Xiaolan Shi, Jingjing Shang, Song Jin, Lingzhi Yan, Depei Wu, Chengcheng Fu

Blood (2025) 146 (Supplement 1): 5782.

https://doi.org/10.1182/blood-2025-5782

Published: 2025

Journal Articles

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Xiaolan Shi, Chengcheng Fu, Lingzhi Yan, Yingying Zhai, Zhi Yan, Jingjing Shang, Song Jin, Xingyue Wu, Hongying You, Shuang Yan, Weiqin Yao, Liqing Kang, Lei Yu, Depei Wu

Blood (2024) 144 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2024-207687

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

MRD Evaluation in a Transplant-Eligible NDMM Study

Yuhe Peng, Chengcheng Fu, Song Jin, Jingjing Shang, Weiqin Yao, Zhi Yan, Yingying Zhai, Li Yao, Hongmiao Shen, Xingyue Wu, Hongying You, Yue Huang, Jing Wang, Jiao Lu, Depei Wu

Blood (2024) 144 (Supplement 1): 6995.

https://doi.org/10.1182/blood-2024-207983

Published: 2024

Journal Articles

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

Chengcheng Fu, Hongying You, Song Jin, Panfeng Wang, Lingzhi Yan, Liying Zhang, Tingting Lu, Xiao Gao, Lei Jiang, Hongchun Qiu, Jingjing Shang, Yingying Zhai, Weiqin Yao, Shuang Yan, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 6992.

https://doi.org/10.1182/blood-2024-210102

Published: 2024

Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li

Blood (2024) 144 (Supplement 1): 4843.

https://doi.org/10.1182/blood-2024-204401

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Song Jin, Lingzhi Yan, Jingjing Shang, Weiqin Yao, Xiaolan Shi, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2024-209260

Published: 2024

Journal Articles

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Lingzhi Yan, Xiaolan Shi, Jing Wang, Song Jin, Ying Yao, Panfeng Wang, Jingjing Shang, Yingying Zhai, Shuang Yan, Yun Xu, Jiajia Meng, Weiqin Yao, Xiao Ma, Chengcheng Fu, Depei Wu

Blood (2024) 144 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2024-205595

Published: 2024

Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li

Blood (2023) 142 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2023-184373

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Zhao Zeng, Chengcheng Fu, Jinlan Pan, Jiao Lu, Jingjing Shang, Zhiyu Zhang, Hongying You, Wanhui Yan, Chunxiao Wu, Qinrong Wang, Qian Wang, Lijun Wen, Song Jin, Lingzhi Yan, Suning Chen, De-pei Wu

Blood (2023) 142 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2023-184504

Published: 2023

Journal Articles

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Xingyue Wu, Chengcheng Fu, Hongmiao Shen, Hongying You, Yingying Zhai, Jing Wang, Zhi Yan, Shuang Yan, Weiqin Yao, Jiao Lu, Jingjing Shang, Song Jin, Xiaolan Shi, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2023-185763

Published: 2023

Journal Articles

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Yingying Zhai, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Shuang Yan, De-pei Wu, Chengcheng Fu

Blood (2023) 142 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2023-185540

Published: 2023

Journal Articles

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2023-185263

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Sustained MRD negativity via multimodal NGS/NGF overcomes high-risk cytogenetics and predicts long-term survival in transplant-eligible multiple myeloma: A real-world cohort study

Treatment of high-risk newly diagnosed multiple myeloma with minimal residual disease-guided therapy：daratumumab, carfilzomib, lenalidomide, and dexamethasone (DKRd)

5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

MRD Evaluation in a Transplant-Eligible NDMM Study

Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only